Plenary III: Bimekizumab Efficacy & Safety Versus Risankizumab in Patients with Active Psoriatic Arthritis: 24-Week Results from a Head-To-Head, Multicenter, Randomized, Phase 3b Study (ACR Convergence 2026) - Sep 8, 2026 - Pres time: Nov 10, 2026; 10:00 AM - 11:30 AM; No abstract available
Clinical • Head-to-Head • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|